Keith T. Flaherty

Harvard University - Harvard Medical School

25 Shattuck St

Boston, MA 02115

United States

Massachusetts General Hospital, Cancer Center

Boston, MA 02114

United States

SCHOLARLY PAPERS

2

DOWNLOADS

21

CITATIONS

1

Scholarly Papers (2)

1.

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial

Number of pages: 148 Posted: 24 Jan 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Harvard University - Harvard Medical School and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 17 (532,825)

Abstract:

Loading...

Mucosal, Melanoma, anti-PD-1 antibody, Axitinib

2.

Melanoma Therapeutic Strategies That Select Against Resistance by Exploiting MYC-Driven Evolutionary Convergence

Number of pages: 79 Posted: 06 Apr 2018
Duke University - Department of Pharmacology and Cancer Biology, Duke University - Department of Statistical Science, Duke University - Department of Pharmacology and Cancer Biology, Harvard University, Harvard Medical School, Brigham and Women's Hospital, Department of Medicine, Genetics Division, Harvard University, Harvard Medical School, Brigham and Women's Hospital, Department of Medicine, Genetics Division, Duke University - Department of Pharmacology and Cancer Biology, Duke University - Department of Pharmacology and Cancer Biology, Case Western Reserve University, School of Medicine, Department of Genetics and Genome Sciences, Duke University - Department of Pharmacology and Cancer Biology, Duke University - Department of Pharmacology and Cancer Biology, Harvard University - Harvard Medical School, Harvard University - Harvard Medical School, Harvard University - Harvard Medical School, Duke University, School of Medicine, Department of Pathology, University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Molecular and Cellular Oncogenesis Program, University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Molecular and Cellular Oncogenesis Program, University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Molecular and Cellular Oncogenesis Program, Case Western Reserve University, School of Medicine, Department of Genetics and Genome Sciences, Duke University - Department of Pharmacology and Cancer Biology, Harvard University, Harvard Medical School, Brigham and Women's Hospital, Department of Medicine, Genetics Division, Duke University - Department of Statistical Science and Duke University - Department of Pharmacology and Cancer Biology
Downloads 4 (613,338)
Citation 1

Abstract:

Loading...